13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung cancer live longer, with a 30% reduction in the risk of death.
Roche Canada announced today that Health Canada has approved Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC), representing the first new treatment for the disease in more than two decades. Tecentriq is the first and only approved cancer immunotherapy agent in Canada for first-line small cell lung cancer.
This approval is based on results from the Phase III IMpower133 study, which is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in first-line treatment of ES-SCLC.